Abaloparatide can protect against osteoporosis by encouraging new bone formation, offering an alternative to existing treatments for non-responsive or intolerant individuals.
Theramex has reached an agreement with the NHS for the pricing of the new drug, which will target those at high risk of bone fractures, especially women post-menopause.
Osteoporosis affects over three million people in the UK, with prevalence increasing significantly with age, making it a major health concern in the older population.
[
Collection
]
[
|
...
]